Introduction
Heart failure (HF) remains a significant global health challenge, with lung congestion serving as its primary clinical hallmark. Traditionally, pulmonary congestion in HF has been viewed through a hemodynamic lens—a "plumbing" issue where inefficient cardiac pumping leads to increased pulmonary venous pressure and subsequent fluid extravasation. However, conventional treatments like diuretics and vasodilators often fail to fully resolve congestion, suggesting that underlying biological mechanisms beyond simple pressure dynamics are at play. This study investigates the metabolic signatures of lung tissue during HF to identify potential therapeutic targets that address the biological roots of pulmonary congestion.
Methods
To explore these metabolic shifts, researchers employed a canine model of chronic heart failure. Eleven male beagles were divided into a sham control group and an HF group. Heart failure was induced in the latter group via six weeks of rapid ventricular pacing (250 beats/min). The HF phenotype was validated through echocardiography, which demonstrated a significant reduction in left ventricular ejection fraction (LVEF) and increased ventricular volume, alongside elevated molecular markers such as BNP mRNA levels.
Lung tissues were harvested and analyzed using Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry (UHPLC-MS/MS) for untargeted metabolomics. Data preprocessing was conducted using XCMS software, and multivariate statistical analyses, including Principle Component Analysis (PCA) and pathway topology analysis via MetaboAnalyst 4.0, were used to identify dysregulated metabolic pathways.
Results
The study revealed profound metabolic remodeling in the lungs of HF subjects, identifying over 160 significantly dysregulated metabolites (81 in positive ion mode and 80 in negative ion mode). Key findings include:
- Arachidonic Acid (AA) Metabolism: This was identified as the most significantly disrupted pathway. The researchers observed a marked decrease in protective metabolites such as epoxyeicosatrienoic acids (EETs), specifically 11,12-EET, and prostaglandins (PGE2, PGI2). EETs are known for their anti-inflammatory and vasodilatory properties; their depletion likely contributes to increased vascular permeability and inflammation in the failing lung.
- Tryptophan-Kynurenine Axis: Tryptophan metabolism was the second most affected pathway. HF lungs showed significantly elevated levels of L-tryptophan, L-kynurenine, and 5-hydroxy-L-tryptophan. These metabolites are associated with endothelial dysfunction and pulmonary hypertension, suggesting a role in the structural damage observed in chronic lung congestion.
- Enzymatic Malfunction: The data suggests widespread dysfunction across the three primary enzymatic pathways for AA: cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P-450 (CYP).
Physiological markers confirmed the model's success, with LVEF dropping from approximately 61% in the sham group to 37% in the HF group, accompanied by increased lung weight indicative of fluid retention.
Discussion and Future Directions
These findings shift the paradigm of lung congestion from a passive fluid accumulation process to an active site of metabolic signaling and remodeling. The identification of the AA and tryptophan pathways as central nodes of dysregulation opens new avenues for the management of HF.
While the study is limited by a small sample size and the specific nature of the pacing-induced model, it provides a critical foundation for future research. Subsequent studies should investigate whether pharmacological modulation of these pathways—such as preventing the breakdown of EETs or inhibiting the kynurenine pathway—can provide a "metabolic diuretic" effect to help manage HF patients more effectively than current volume-based therapies.
Summary updated